T-CURX GmbH
PrivateLast Round
Series A
Dec 17, 2025
Total Funding Raised
$20.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
T-CURX GmbH operates in Healthcare & Life Sciences and is based in Würzburg. Its latest recorded funding round was a Series A round in December 2025.
T-CURX GmbH is a biotechnology company that develops and commercializes next-generation CAR-T cell therapies for cancer using proprietary non-viral, transposon-based gene transfer technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
T-CURX GmbH Comparables
Compare T-CURX GmbH with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| A-SEEDS Co., Ltd. | 83% | |
| Integra Therapeutics | 81% | |
| Carla BioTherapeutics | 79% |
For institutional investors. Book with your work email.
T-CURX GmbH Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 17, 2025 | ||||
| Grant | Dec 15, 2020 | ||||
| Grant | Jan 2, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
T-CURX GmbH Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series A |
| BioMedPartners | Series A |
| Highlight Capital | Series A |
| Innovative Health Initiative | Grant |
| European Commission | Grant |
| Bayern Kapital | Series A |
| Bavarian State Ministry of Economic Affairs, Regional Development and Energy | Pre Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 117% MoM.
- Jul 29, 2026
Monthly visitors increased 830% MoM, from 115 to 1.1K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 30, 2026
T-CURX GmbH appointed Florian Schmid Chief Financial Officer on Sep 30th '26, with responsibility for finance, operations, and investor relations and an initial focus on preparing and executing planned financing activities.
For institutional investors. Book with your work email.
T-CURX GmbH Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about T-CURX GmbH's valuation, stock price, and market status.
Is T-CURX GmbH a public or private company?
T-CURX GmbH is a private company.
What is the current stock price of T-CURX GmbH?
T-CURX GmbH is a private company, so its shares have no public market price. Caplight tracks T-CURX GmbH's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is T-CURX GmbH worth (valuation)?
Valuation information for T-CURX GmbH is not publicly available.
Can I buy T-CURX GmbH stock?
T-CURX GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was T-CURX GmbH's last funding round?
T-CURX GmbH's most recent funding round was Series A on December 17, 2025.
Who are the main investors in T-CURX GmbH?
Key investors in T-CURX GmbH include BioMedPartners.
Will T-CURX GmbH IPO soon?
No public IPO plans have been announced for T-CURX GmbH.
How can I track T-CURX GmbH secondary market activity?
Caplight tracks bids, offers, and trades in T-CURX GmbH's shares on secondary markets.